A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas

LESSONS LEARNED. The combination of the antiangiogenic agent ziv‐aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested. Studies such as these emphasize the importance of con...

Descripción completa

Detalles Bibliográficos
Autores principales: Meehan, Robert, Kummar, Shivaani, Do, Khanh, O'Sullivan Coyne, Geraldine, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Doroshow, James H., Chen, Alice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291327/
https://www.ncbi.nlm.nih.gov/pubmed/29853657
http://dx.doi.org/10.1634/theoncologist.2018-0203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291327/
https://www.ncbi.nlm.nih.gov/pubmed/29853657
http://dx.doi.org/10.1634/theoncologist.2018-0203

Ejemplares similares